FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/18/2022
Back to search
Official data from USPTO
CELL TECHNA GENE THERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
07/18/2022
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
10/14/2020
Registration date
01/11/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/11/2022
Last transaction
01/11/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
16
Owner location
LT
Examiner
LIEBL, ALEXANDRA
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "CELL TECHNA" in dark blue where the wording "CELL" is within four stylized curved bands. The top left and lower right curved bands are orange, the top right and lower left smaller bands are dark blue. Underneath the wording "TECHNA" is the stylized wording "gene therapy" in orange.
Holders and representatives
Holders
UAB "NORTHWAY TURTO VALDYMAS"
Representatives
John Zaccaria Notaro, Michalos & Zaccaria P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of oncologicalcardiovascularrespiratoryinflammatoryautoimmune and degenerative diseases and disordersrheumatoid arthritismultiple sclerosisallergies and COVID-19; drugs for medical purposespharmaceutical preparations for the treatment of oncologicalcardiovascularrespiratoryinflammatoryautoimmune and degenerative diseases and disordersrheumatoid arthritismultiple sclerosisallergies and COVID-19
Class 42
Scientific and technological servicesresearch and design in the field of products and processes development of biotechnology products and processes; bacteriological research; biological research; chemistry services in the nature of product development and quality control of biotechnology products; chemical research; conducting clinical trials for others; scientific research; scientific laboratory services; technological consultation in the field of development of manufacturing processes for biotechnology products
Class 44
Medical services; midwife services; alternative medicine services; in vitro fertilization services; chiropractic services; physiotherapy; occupational therapy services; human tissue bank services; hospital services; rental of medical equipment; medical advice for individuals with disabilities; medical clinic services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical assistance; opticians' services; plastic surgery; services of a psychologist; convalescent home services; preparation of prescriptions by pharmacists; rehabilitation of substance abuse patients; nursingmedical; health centre services; health counselling; medical screening; health care; telemedicine services
Publications
History of USPTO decisions and trademark events.
34 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/27/2022
FIMP
FINAL DISPOSITION PROCESSED
06/27/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/11/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/11/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/26/2021
PUBO
PUBLISHED FOR OPPOSITION
10/26/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/06/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/20/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
09/20/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/20/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
09/20/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/20/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/15/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/14/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/14/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/14/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/14/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
09/14/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/14/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/14/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/14/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/16/2021
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
05/18/2021
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
05/16/2021
RFNT
REFUSAL PROCESSED BY IB
04/13/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/22/2021
RFRR
REFUSAL PROCESSED BY MPU
03/22/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/18/2021
CNRT
NON-FINAL ACTION WRITTEN
03/17/2021
DOCK
ASSIGNED TO EXAMINER
03/15/2021
MAFR
APPLICATION FILING RECEIPT MAILED
01/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/02/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/31/2020
Continuous trademark protection
Get notified about every new filing that threatens CELL TECHNA GENE THERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.